Generate:Biomedicines ("Generate") today announced it plans to initiate two global Phase 3 clinical trials, SOLAIRIA-1 and SOLAIRIA-2, evaluating GB-0895 in approximately 1,600 adults and adolescents ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback